{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-002118","form_type":"8-K/A","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.451373+00:00","generated_at":"2026-06-06T23:47:33.181372+00:00","sec_items":["2.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BC 9M 2023 revenue $86.3M, net income $18.8M; Gyre Therapeutics files financials for acquired entity","bullets":["BC revenue $86.3M for 9M 2023 vs $77.4M in 9M 2022 (+11.5%); net income $18.8M vs $2.3M.","Operating income $25.0M in 9M 2023, up from $7.2M in prior year period.","Cash and CDs total $46.9M as of Sep 30, 2023; equity $83.8M.","Business combination closed Oct 30, 2023; filing provides required historical financials of BC.","Pro forma combined financials also filed as Exhibit 99.2."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-002118","json":"https://secwatch.observer/filing/0001140361-24-002118.json","markdown":"https://secwatch.observer/filing/0001140361-24-002118.md","text":"https://secwatch.observer/filing/0001140361-24-002118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124002118/0001140361-24-002118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124002118/ef20018550_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:47:33.181372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}